These findings, coupled with the observed efficacy of I-DXd in combination with PD-1 blockade, underscore the therapeutic potential of targeting ICAM1 in cervical cancer, particularly in TMEs characterized by high mutational burdens and suppressed immune responses [58–61]. This evidence concerns the gene ICAM1 and cervical cancer.